On October 5, 2026 GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, reported it will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri multi-cancer early detection (MCED) test at the Early Detection of Cancer Conference (EDCC) in Edinburgh, the United Kingdom, taking place Oct. 6-8, 2026, and at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 in Madrid, Spain taking place Oct. 23-27, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Data across both meetings will include:
A rapid oral presentation highlighting the efficiency and safety of Cancer Signal Origin (CSO) guided diagnostic workups.
A poster showing Galleri cancer detection of more than 200 cancers across histologically distinct cancer types, including rare cancers.
A poster showing Galleri cancer detection performance and accuracy across self-reported racial and ethnic groups.
A poster presenting new NHS-Galleri data on the preclinical window for cancer detection with findings compatible with annual MCED screening.
A poster showing a reduction of cancer diagnoses in emergency presentations associated with annual Galleri screenings.
"Ongoing analyses of PATHFINDER 2 and NHS-Galleri trial data continue to strengthen the evidence for integrating multi-cancer early detection into routine care," said Josh Ofman, MD, MSHS, CEO at GRAIL. "Across large, diverse populations, these data continue to demonstrate Galleri’s strong performance and favorable safety profile, and reinforce its potential to fundamentally improve how we screen for cancer by finding more cancers, before symptoms are present, in early stages, when there is the greatest opportunity for curative intent treatment."
EDCC Data Presentations
Title: Estimating Preclinical Detection Window, Multi-Cancer Early Detection (MCED) Test Sensitivity, and Episode Sensitivity in the NHS-Galleri Trial Using the Incidence Method
Presentation Type: Poster
Date: Oct. 6
Title: Spectrum of Histologically Distinct Cancer Types Detected by a Methylation-Based Multi-Cancer Early Detection (MCED) Test
Presentation Type: Poster
Date: Oct. 7
Title: Performance of a multi-cancer early detection (MCED) test across racial and ethnic groups: Descriptive report from PATHFINDER 2
Presentation Type: Poster
Date: Oct. 7
Title: Loss of Life Expectancy by Stage at Diagnosis and Cancer Type in England: Illustrating the Burden of Premature Mortality From Late-Stage Cancer
Presentation Type: Poster
Date: Oct. 6
Title: High adherence to mammography screening before and after MCED testing
Presentation Type: Poster
Date: Oct. 7
Title: Population Impact of MCED Screening by Reducing the Diagnosis of Cancer in Emergency Settings in England
Presentation Type: Poster
Date: Oct. 7
More information about timing of the EDCC presentations can be found here.
ESMO Data Presentations
Title: Efficiency and Safety of Cancer Signal Origin (CSO)-Guided Diagnostic Workups Following Multi-Cancer Early Detection (MCED) Testing: Results from PATHFINDER 2 (PF2)
Abstract Number: 1151
Presentation Type: Rapid Oral
Date/Time: Oct. 26, 2:45 p.m.-4:15 p.m.
Location: Salamanca Auditorium, Hall 10
Title: Diagnostic Workups Following a Positive Multi-Cancer Early Detection (MCED) Blood Test in Clinical Practice
Presentation Number: 1164P
Presentation Type: Poster
Date/Time: Oct. 25, 12 p.m.-12:45 p.m.
More information about timing of the ESMO (Free ESMO Whitepaper) presentations can be found here.
(Press release, Grail, OCT 5, 2026, View Source [SID1234673190])